We speculate that RelB may exert pivotal effects on tumor cell proliferation in our patients with NSCLC, since many patients with this tumor type have been consistently and repetitively shown to feature all kinds of TP53 perturbations, including copy number alterations and point mutations, while a significant proportion retain the wild-type tumor suppressor. Here, RELB is linked to non-small cell lung carcinoma.